The EU Commission has published a "Results in Brief" article on ATXA Therapeutics' EU-funded PAH-HOPE project. Entitled "New Hope for...

ATXA will be presenting preclinical efficacy results of its lead drug candidate NTP42 for treatment of PAH at the European Society of...

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a further preclinical model of...

Well done to the ATXA Team, who gave a presentation at the World Orphan Drug Virtual Conference on Monday 17th August. They presented on...

ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience...

https://www.irishtimes.com/business/technology/atxa-therapeutics-looks-to-raise-30m-to-secure-regulatory-approval-1.4314023

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a preclinical model of pulmonary...

The companies driving Ireland's entrepreneurial edge. ATXA Therapeutics Ltd is delighted to be recognised amongst such a fantastic list...

We’re here at the ERS Congress 2019 where we will be presenting the our preclinical findings of NTP42 for the treatment of PAH. Please...

We're here! Drop by the Poster Area for the session on "Pulmonary Arterial Hypertension ‑ Treatments" and talk to us about our...

ATXA Therapeutics and PAH-Hope team members, Prof. Therese Kinsella & Dr. Helen Reid are looking forward to the ESC Congress 2019 next...